Hydrochlorothiazide + henagliflozin proline

Hydrochlorothiazide + henagliflozin proline is a fixed-dose combination of two oral small molecule drugs used primarily for the management of type 2 diabetes mellitus and hypertension. Henagliflozin proline is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor developed to improve glycemic control by preventing renal glucose reabsorption, thereby increasing urinary glucose excretion[1][2][5]. Hydrochlorothiazide is a thiazide diuretic and antihypertensive agent that acts on the distal convoluted tubule in the kidney to inhibit sodium reabsorption, leading to increased excretion of sodium and water[7]. The combination has been studied for pharmacokinetic interactions, showing no clinically meaningful safety concerns when co-administered[1][2]. Henagliflozin proline is under development by Jiangsu Hengrui Medicine for chronic kidney disease and unspecified cancer, while it is already indicated as Ruiqin for type 2 diabetes mellitus in China[5].

Brand names

RuiqinMicrozideEsidrexHydrodiurilOretic

Other names

HCTZ